941 Shares in Natera, Inc. (NASDAQ:NTRA) Bought by Whipplewood Advisors LLC

Whipplewood Advisors LLC purchased a new position in Natera, Inc. (NASDAQ:NTRA) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 941 shares of the medical research company’s stock, valued at approximately $149,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NTRA. Principal Securities Inc. grew its stake in shares of Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after buying an additional 59 shares during the period. Gladstone Institutional Advisory LLC grew its stake in Natera by 1.7% in the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company’s stock valued at $574,000 after acquiring an additional 61 shares during the period. Silver Oak Securities Incorporated increased its holdings in shares of Natera by 3.1% during the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company’s stock valued at $470,000 after acquiring an additional 89 shares in the last quarter. Covestor Ltd raised its position in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the period. Finally, Blue Trust Inc. lifted its holdings in shares of Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Natera news, insider John Fesko sold 663 shares of Natera stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the sale, the insider now owns 156,044 shares of the company’s stock, valued at approximately $27,739,941.88. The trade was a 0.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Michael Burkes Brophy sold 1,442 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $161.87, for a total transaction of $233,416.54. Following the completion of the sale, the chief financial officer now directly owns 108,032 shares in the company, valued at approximately $17,487,139.84. This trade represents a 1.32 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 295,772 shares of company stock valued at $49,741,699. Company insiders own 7.60% of the company’s stock.

Natera Stock Down 2.5 %

Natera stock opened at $156.61 on Friday. Natera, Inc. has a fifty-two week low of $75.18 and a fifty-two week high of $183.00. The stock has a market cap of $20.68 billion, a PE ratio of -88.98 and a beta of 1.66. The firm’s 50-day simple moving average is $167.59 and its 200 day simple moving average is $146.60. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Research analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on NTRA. Piper Sandler boosted their price target on shares of Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research note on Monday, November 18th. JPMorgan Chase & Co. lifted their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Guggenheim lifted their price objective on shares of Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. Craig Hallum lifted their price objective on shares of Natera from $121.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Robert W. Baird lifted their price objective on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $170.94.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.